«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2017年第5期

页码:

610-613

栏目:

综述

出版日期:

2017-03-25

文章信息/Info

Title:

Definition of valvular atrial fibrillation and progress in anticoagulation therapy

作者:

孙述昱¹; 吴 宾²; 樊苗苗²; 易 甫²

（第四军医大学：1.学员一旅，2.西京医院心血管内科，陕西 西安 710032）

Author(s):

SUN Shu-yu¹;  WU Bin²;  FAN Miao-miao²;  YI Fu²

(1.First Cadet Brigade；
2.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:

心房颤动; 非瓣膜性房颤; 瓣膜性房颤; 血栓栓塞; 新型口服抗凝药物

Keywords:

atrial fibrillation;  non-valvular atrial fibrillation;  valvular atrial fibrillation;  thrombo-embolic;  non-VKA oral anticoagulants

分类号:

R541.7

DOI:

-

文献标识码:

A

摘要:

现阶段对于“瓣膜病变型”房颤（AF）与“非瓣膜病变型”AF的定义尚未达成共识，不仅如此，各指南在表述这些概念时也存在差异。临床试验对于“瓣膜病变型”AF与“非瓣膜病变型”AF定义的阐述不甚理想。两类AF血栓栓塞风险差异较大，抗凝治疗策略也有所不同。本文将对瓣膜性AF定义及抗凝治疗的研究进展予以综述。

Abstract:

There is no consensus on the definition of “valvular disease” atrial fibrillation and “non valvular disease” atrial fibrillation and there are also different explanations in these concepts provided by different guidebooks. The definitions of “valvular disease” and “non valvular disease” from clinical trials are not ideal. In fact, the two types of atrial fibrillations are very different in their risk of thromboembolism and so are their anticoagulant treatment strategies. This article will review the definition of valvular atrial fibrillation and its progress in anticoagulation therapy.

参考文献/References

[1]黄从新，张 澍，黄德嘉，等.心房颤动:目前的认识和治疗建议—2015[J].中国心脏起搏与心电生理杂志,2015(05):377-434.
[2]Granger CB,Alexander JH,Mcmurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
[3]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[4]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[5]Breithardt G,Baumgartner H,Berkowitz SD,et al.Clinical characteristics and outcomes with rivaroxaban vs.warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial[J].Eur Heart J,2014,35(47):3377-3385.
[6]Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J,2012,33(21):2719-2747.
[7]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130(23):2071-2104.
[8]Heidbuchel H,Verhamme P,Alings M,et al.Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation[J].Europace,2015,17(10):1467-1507.
[9]Molteni M,Polo FH,Primitz L,et al.The definition of valvular and non-valvular atrial fibrillation:results of a physicians' survey[J].Europace,2014,16(12):1720-1725.
[10]Kirchhof P,Ammentorp B,Darius H,et al.Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation:primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)[J].Europace,2014,16(1):6-14.
[11]Lip GY,Laroche C,Dan GA,et al.A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation(EORP-AF)Pilot General Registry[J].Europace,2014,16(3):308-319.
[12]Whitlock RP,Sun JC,Fremes SE,et al.Antithrombotic and thrombolytic therapy for valvular disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e576S-e600S.
[13]Philippart R,Brunet-Bernard A,Clementy N,et al.Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’and valvular heart disease:the Loire Valley Atrial Fibrillation Project[J].Eur Heart J,2015,36(28):1822-1830.
[14]Rowe JC,Bland EF,Sprague HB,et al.The course of mitral stenosis without surgery:ten- and twenty-year perspectives[J].Ann Intern Med,1960,52:741-749.
[15]De Caterina R,Camm AJ.What is‘valvular’atrial fibrillation? A reappraisal[J].Eur Heart J,2014,35(47):3328-3335.
[16]Bonow RO, Carabello BA,Chatterjee K,et al.2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease[J].Circulation,2008,118(15):e523-e661.
[17]Vahanian A,Alfieri O,Andreotti F,et al.Guidelines on the management of valvular heart disease(version 2012)[J].Eur Heart J,2012,33(19):2451-2496.
[18]Cannegieter SC,Rosendaal FR,Briet E.Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses[J].Circulation,1994,89(2):635-641.
[19]Cannegieter SC,Rosendaal FR,Wintzen AR,et al.Optimal oral anticoagulant therapy in patients with mechanical heart valves[J].N Engl J Med,1995,333(1):11-17.
[20]Kontozis L,Skudicky D,Hopley MJ,et al.Long-term follow-up of St.Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation:an analysis of the temporal distribution of causes of death[J].Am J Cardiol,1998,81(6):736-739.
[21]You JJ,Singer DE,Howard PA,et al.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e531S-e575S.
[22]Miyasaka Y,Tsuji H,Tokunaga S,et al.Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation[J].Int J Cardiol,2000,72(3):229-233.
[23]Fukuda N,Hirai T,Ohara K,et al.Relation of the severity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation[J].Int J Cardiol,2011,146(2):197-201.
[24]Nakagami H,Yamamoto K,Ikeda U,et al.Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation[J].Am Heart J,1998,136(3):528-532.
[25]Fauchier L,Philippart R,Clementy N,et al.How to define valvular atrial fibrillation?[J].Arch Cardiovasc Dis,2015,108(10):530-539.
[26]Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement(RE-ALIGN)[J].Am Heart J,2012,163(6):931-937.
[27]Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves[J].N Engl J Med,2013,369(13):1206-1214.

备注/Memo

备注/Memo:

收稿日期：2016-07-07.
基金项目：国家自然科学基金项目资助（81470479）；陕西省社会发展科技攻关项目资助（2014K11-03-01-04；2014K12-07）
通讯作者：易甫，副教授，主要从事心律失常的防治研究 Email：yi12fu56@hotmail.com
作者简介：孙述昱，本科生 Email：903524854@qq.com 共同第一作者：吴宾，硕士生 Email：wubin0917@163.com

常用功能

更新日期/Last Update: 2017-04-20